argenx SE (NASDAQ:ARGX) Given Consensus Rating of “Moderate Buy” by Brokerages

argenx SE (NASDAQ:ARGX) has been given an average recommendation of “Moderate Buy” by the twenty-two brokerages that are presently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $547.74.

A number of analysts recently commented on the company. Robert W. Baird lifted their price objective on argenx from $490.00 to $515.00 and gave the stock an “outperform” rating in a research report on Monday, July 29th. Wells Fargo & Company lifted their price target on argenx from $543.00 to $547.00 and gave the company an “overweight” rating in a report on Friday, July 26th. HC Wainwright lifted their price target on argenx from $504.00 to $533.00 and gave the company a “buy” rating in a report on Friday, July 26th. Stifel Nicolaus lifted their price objective on argenx from $485.00 to $500.00 and gave the company a “buy” rating in a research note on Monday, June 24th. Finally, Bank of America reaffirmed a “buy” rating and issued a $607.00 price objective (up from $535.00) on shares of argenx in a research note on Monday, June 24th.

argenx Stock Up 0.4 %

Shares of ARGX stock opened at $538.01 on Friday. argenx has a fifty-two week low of $327.73 and a fifty-two week high of $554.74. The stock has a market cap of $32.17 billion, a P/E ratio of -95.05 and a beta of 0.62. The business has a fifty day simple moving average of $505.20 and a 200-day simple moving average of $427.69.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $1.34. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. The business had revenue of $489.43 million during the quarter, compared to analysts’ expectations of $436.66 million. During the same quarter last year, the business posted ($1.69) earnings per share. On average, sell-side analysts anticipate that argenx will post -0.37 earnings per share for the current year.

Hedge Funds Weigh In On argenx

A number of institutional investors have recently made changes to their positions in ARGX. Blue Trust Inc. increased its holdings in shares of argenx by 620.0% in the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock valued at $28,000 after acquiring an additional 62 shares during the last quarter. J.Safra Asset Management Corp grew its stake in argenx by 590.0% during the 2nd quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock worth $30,000 after buying an additional 59 shares during the last quarter. GAMMA Investing LLC grew its stake in argenx by 420.0% during the 1st quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock worth $31,000 after buying an additional 63 shares during the last quarter. Mather Group LLC. bought a new position in argenx during the 1st quarter worth $38,000. Finally, Point72 Hong Kong Ltd bought a new position in argenx during the 2nd quarter worth $76,000. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.